Because the natural FXR-ligand CDCA has a high potential to induce cellular damage, synthetic FXR-ligands, especially OCA, have already been evaluated in clinical trials and would be useful therapeutic agents as an early treatment for fatty liver. The gene discussed is NR1H4; the disease is Hepatic steatosis.